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Neural crest migration is critical to its physiological function. Mechanisms controlling
mammalian neural crest migration are comparatively unknown, due to difﬁculties accessing
this cell population in vivo. Here we report requirements of glycogen synthase kinase 3
(GSK3) in regulating the neural crest in Xenopus and mouse models. We demonstrate that
GSK3 is tyrosine phosphorylated (pY) in mouse neural crest cells and that loss of GSK3 leads
to increased pFAK and misregulation of Rac1 and lamellipodin, key regulators of cell migra-
tion. Genetic reduction of GSK3 results in failure of migration. We ﬁnd that pY-GSK3
phosphorylation depends on anaplastic lymphoma kinase (ALK), a protein associated with
neuroblastoma. Consistent with this, neuroblastoma cells with increased ALK activity express
high levels of pY-GSK3, and blockade of GSK3 or ALK can affect migration of these cells. All
together, this work identiﬁes a role for GSK3 in cell migration during neural crest develop-
ment and cancer.
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The neural crest is a vertebrate-speciﬁc, motile population ofcells born at the junction of the neural and non-neuralectoderm. This lineage has contributed to our under-
standing of cellular behaviours, such as contact inhibition of
locomotion1. It is the origin of many cell types found throughout
the organism, including melanocytes, peripheral neurons, cardiac
outﬂow tract and the craniofacial skeleton. Recent reports have
highlighted the importance of neural crest cells: their stem-like
capacity, their ability to reprogram, to become cancerous, and to
drive vertebrate evolution2,3. The highly migratory activity of
these cells is critical to their in vivo function, not only are their
ultimate tissue descendants widespread in the organism but also
failure to regulate migration and differentiation in the correct
locations is associated with diseases like neuroblastoma (NB)4–6.
Despite its importance, the speciﬁc mechanisms underlying this
migratory activity and its control are poorly understood.
In our previous work, we demonstrated a critical role for the
pleiotropic kinase glycogen synthase kinase 3 (GSK3) in cranio-
facial development7; therefore, we sought to understand the
regulation of GSK3 in neural crest cells, which are integral to
most of the craniofacial structures. In vertebrates, the serine/
threonine kinase GSK3 is encoded by two paralogous genes,
GSK3α and GSK3β, which are nearly identical throughout their
kinase domains8,9, and have >100 predicted substrates9,10. The
effect of GSK3 phosphorylation is substrate dependent and
variable, ranging from control of protein degradation (β-catenin,
MYC) and localization (nuclear factor of activated T cells) to
trafﬁcking (amyloid precursor protein) and cleavage (Gli)9.
Given the seemingly ubiquitous expression of GSK3, it is not
surprising that ﬁne-tuning of this kinase activity is very complex
and not well understood, especially in vivo. GSK3 can be inhib-
ited by N-terminal serine phosphorylations on both GSK3α
(serine-21/S21) and GSK3β (serine-9/S9). These serines are tar-
geted by kinases such as protein kinase A and protein kinase B
(PKB/AKT) and phosphorylation at these serines prevents GSK3
binding to its substrates11. However, interestingly, mouse
mutants carrying non-phosphorylatable alanine substitutions at
these sites (GSK3αS21A/S21A; GSK3βS9A/S9A) have no obvious
developmental phenotypes and are fertile11. Using this rigorous
approach, functional defects in these animals were limited to
regulation of glycogen synthase activity in response to insulin11.
This evidence, that regulation of GSK3 via PKB-dependent serine
phosphorylation is dispensible for embryogenesis, raises the
possibility that additional regulatory mechanisms may be
important for GSK3 activity in utero. Indeed, inhibition of GSK3
activity by Wnt ligands is serine independent. Instead, inhibition
appears to occur via sequestration of GSK3 in response to
ligand12. This suggests that there exist distinct pools of GSK3
within the cell that are poised for activity.
One positive regulatory mechanism may be via phosphoryla-
tion of conserved tyrosine residues (GSK3α-Y279, GSK3β-Y216),
which can change the target selectivity of GSK313. While these
can be autophosphorylations14,15, a recent computational study
identiﬁed GSK3α as a speciﬁc substrate for the kinase ALK, which
is often pathologically increased in NB cells16. However, these in
silico predictions had not been validated in vivo and there had
been no studies describing the tissue localization of this phos-
phorylation. Given the importance of ALK in pathogenesis of
neural crest-derived cancers, we considered the possibility that
phosphorylation of these tyrosines might be an important
mechanism for ALK-dependent tuning of GSK3 activity, which
should be speciﬁc to the neural crest lineage. Indeed, we identiﬁed
speciﬁc expression of ALK and phospho-tyrosine GSK3 in the
delaminating neural crest cells, as well as a requirement for GSK3
in the control of neural crest and NB cell migration.
As noted above, GSK3 is notoriously promiscuous, with many
predicted substrates. This has led to reported targets involved in a
broad range of biological processes, such as senescence, cell
proliferation, axonal outgrowth and signaling. GSK3 is also
considered a prime therapeutic target in diverse diseases, such as
diabetes, depression, neurodegeneration, cancer and retinitis
pigmentosa17,18. As a consequence, it is thought that regulation of
GSK3 target selection is very context dependent.
Even focussing on the neural crest lineage, GSK3 is thought to
have multiple sequential roles beginning with a requirement in
patterning of the dorsal axis19–21. Based primarily on data from
chicken and frog, neural crest-speciﬁc GSK3 targets include the
Wnt effector β-catenin, the metalloprotease ADAM13 and tran-
scription factors snail and twist22–24. Wnt-dependent inhibition
of GSK3 is clearly necessary for β-catenin-mediated transcrip-
tional activation during neural crest induction25. GSK3 also has
proposed roles in the phosphorylation of Twist and Snail, pro-
teins which can regulate the activity and stability of these targets,
thus controlling the onset of the epithelial–mesenchymal transi-
tion (EMT)22. Concurrently, GSK3 interactions with ADAM13
are proposed to be crucial for delamination and entry into the
EMT23. Given the variety of substrates and the precise timing of
development, there is no doubt that GSK3 activity must to be
dynamically regulated during neural crest development. However,
as noted, mice lacking the inhibitory phosphorylation sites at S21/
S9-GSK3α/β have normal craniofacial development and are
viable11. Therefore, we focus on positive regulation of GSK3 via
activating tyrosine phosphorylations.
Here we ﬁnd a speciﬁc activation of GSK3 in neural crest cells
as they depart from the neuroepithelium and become migratory
mesenchymal cells. This activation is controlled by ALK, which
has been implicated in NB and other cancers. Genetic and
pharmacological loss of GSK3 activity leads to cytoskeletal
changes in migratory neural crest (mNC) cells as well as in NB,
raising the possibility that control of GSK3 is a rapid and
reversible mechanism for controlling cell migration dynamics in
the neural crest lineage.
Results
GSK3 is tyrosine phosphorylated in migrating neural crest. In
the embryo, neural crest cells are induced at the neuroepithelial
border, subsequently delaminating and becoming migratory. To
conﬁrm whether GSK3 was preferentially enriched during neural
crest cell migration, we examined mRNA and reporter gene
expression for both paralogous genes in frog and mouse and
found that these genes were indeed expressed in mNC (Fig. 1a–j).
We noted in particular the enrichment of GSK3 expression in the
neural plate (NP) stages, at the border of the NP (Fig. 1e, f, h, i)
and later on in the mNC cell population, including that destined
for the ﬁrst branchial arch (marked by 1, Fig. 1b, d, g, i). The close
protein similarity between GSK3 in frog and mouse, as well as the
similar expression patterns, suggests that GSK3 activity may play
a conserved role in the vertebrate neural crest.
We were then curious whether GSK3 proteins were activated at
speciﬁc time points during murine neural crest development. To
address this, we used an antibody recognizing a phosphorylated
tyrosine in the active site of both GSK3 isoforms (pY279-GSK3α/
pY216-GSK3β, referred to hereafter as pY-GSK3). These sites are
identical in the two proteins. pY-GSK3 (green) was speciﬁcally
detected in the cranial neural crest cell population (marked by
P75-NTR, red) after emigration from the neural tube (Fig. 1k).
This was in contrast to more widespread mRNA expression of
GSK3α/β seen above (Fig. 1e–j). This phosphorylation was also
conﬁrmed in a simple ex vivo culture system, which allows us to
visualize and manipulate speciﬁc neural crest populations without
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complications from surrounding tissues (Fig. 1l). In these assays,
NPs from embryonic day 8.5 (e8.5) mouse embryos were
explanted and cultured in vitro, prior to neural crest migration,
allowing subsequent examination of delaminating neural crest
cells. By 24 h of culture, the premigratory neural crest (pNC) cells
are spread in an epithelial sheet surrounding the NP, with fully
mNC in the outer ring (Fig. 1m). Again, we noted that pY-GSK3
is speciﬁcally found in neural crest cells just when they
delaminate and become mesenchymal (Fig. 1n–o). In fully
mNC cells, the majority of pY-GSK3 appears perinuclear and is
invariably oriented in the direction of migration (Fig. 1p). In
contrast, staining for total GSK3 appears diffuse and ubiquitous
(Fig. 1q).
Loss of GSK3 prevents migration of cranial neural crest. We
then turned to mouse mutants to determine the in vivo genetic
requirements for GSK3 in the neural crest. To do this, we gen-
erated embryos with a conditional deletion of both GSK3α and
GSK3β genes using a neural crest-speciﬁc cre-recombinase driver
pNC
mNC
G
SK
3α
G
SK
3β
a b
c d
G
SK
3α
la
cZ
G
SK
3β
la
cZ
e
Xenopus laevis Mus musculus
1
23
ov
ov
f g
12
h
ov
h i j
Neural
plate
Neural
crest
Hoescht Anti-pY-GSK3 MergeP75-NTR
Hoescht Anti-pY-GSK3 MergeP75-NTR
pNC
mNC
k
n
Hoescht Anti-pY-GSK3 MergeP75-NTRp
Pr
em
ig
ra
to
ry
 N
C
M
ig
ra
to
ry
 N
C
E9
, M
ou
se
 n
eu
ra
l t
ub
e
mNC
p75/pY-GSK3/Hoescht
o
NP
mNC
pNC
q
123
1
l
NPB
NPB
24
hours
Total GSK3/Hoescht 
m
Explant
Fig. 1 GSK3 genes are expressed during neural crest migration in the frog Xenopus laevis and mouseMus musculus. a, bmRNA in situ hybridization for Gsk3α
in X. laevis at stage (st) 25 (a) show expression in the pharyngeal pouches, brain, spinal cord and eye vesicle (b). c, d In situ hybridization for Gsk3β in X.
laevis at st 25 (c). GSK3β is expressed in the pharyngeal pouches and the spinal cord as well as regions of the brain (d, scale bar= 0.5 mm). e–g GSK3αlacZ
is expressed in mice during neural crest migration stages. e, f In an e8.5 embryo GSK3αlacZ is expressed in the cephalic mesenchyme, in the
neuroepithelium and in the cephalic neural fold. g By e9.5–10, GSK3αlacZ is expressed in the ﬁrst and second branchial arches (1 and 2) and the frontonasal
prominence. h–j GSK3βlacZ is expressed in mice when neural crest is actively migrating. h, i In e8.5 embryos GSK3βlacZ is mainly expressed in the
neuroectoderm, restricted to the prospective hindbrain and some areas in the mesenchyme, scale bar= 200 µm. j At e9.5, GSK3βlacZ is mainly expressed in
BA1 and cranial ganglia and in the presumptive trigeminal ganglion. k–p GSK3α/β are phosphorylated at tyrosines Y216/279 during cranial neural crest cell
migration. k Transverse cranial section of e9 mouse showing immunoﬂourescent staining for Hoechst/DNA (blue), pY-GSK3 (green) and p75NTR (neural
crest, red). l Schematic of e8.5 mouse embryo depicting cranial neural crest (CNC) dissection. m Bright-ﬁeld image of mouse neural crest explant. Two
types of cells surround the NP: premigratory neural crest (pNC) cells that are epithelial and migratory neural crest (mNC) scale bar, 250 μm. n Cells
migrating away from the pNC begin to express pY-GSK3. pNC to the left. All neural crest express p75NTR (red). Note in merge that perinuclear expression
of pY-GSK3 is invariably oriented in direction of migration (o, white arrowheads). pmNC cells express pYGSK3 (green) and p75-NTR (red). n, p scale bars
= 25 µM. q Expression of total GSK3 is ubiquitous in pNC and mNC cells. Scale bar= 25 µM. All are representative images from at least three independent
experiments
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(Wnt1::cre26). By e9.5, we found widening of the NP (Fig. 2a, e,
red bracket), with a medial expansion of Sox10 expression
(Fig. 2a, e, asterisk). By e10.5, dorsal views revealed an accumu-
lation of Sox10-positive cells in the brain (compare Fig. 2b–f, red
bracket), suggesting that the cranial neural crest cells have failed
to migrate from the neural tube. Complete nulls had a severe
disruption of cell migration to the facial prominences, the bran-
chial arches and the cranial ganglia (compare Sox10-positive/blue
in Fig. 2c, d to 2g, h). Because we rarely found animals surviving
beyond e11.5, we also examined animals carrying a single allele of
functional GSK3 (Wnt1::cre; GSK3αﬂ/+;βﬂ/ﬂ or Wnt1::cre;
GSK3αﬂ/ﬂ;βﬂ/+). In both cases, we noted a reduction in Sox10-
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positive cells en route to the ﬁrst branchial arch and an accu-
mulation of positive staining in the neural tube, suggesting that
both GSK3 proteins contribute to migration of the neural crest
(Supplementary Figure 1A,C,E,G red bracket and B,D,F,H dotted
square).
While the timing of the Wnt1::cre transgene misses the
initiation of neural crest induction, it was still possible that some
of the effects seen were due to GSK3 requirements in the pNC. In
order to bypass early effects on the neural crest, we turned to
pharmacological inhibition of GSK3 using the speciﬁc inhibitor
BIO (6-bromoindirubin-3′-oxime)27. Making use of Xenopus
allowed us to precisely time our manipulations in a well-deﬁned
in vivo system. Treatments of Xenopus embryos conﬁrmed that
GSK3 inhibition led to loss of the migration marker twist1
(Fig. 2i). Treatment of Xenopus embryos at stage 12.5 conﬁrmed
that GSK3 inhibition led to loss of twist1. When the embryos
were released from treatment at stage 19, we found some recovery
of twist1 expression (Fig. 2k). Loss of GSK3 function during the
critical stages led to signiﬁcant changes in face shape as well as a
smaller neural crest-derived tail ﬁn (Supplementary Figure 2A-C),
as well as loss of the neural crest-derived facial cartilages (Fig. 2j,
l). Although the facial cartilages were lost leading to narrowing of
the head, the mesodermal cranial muscles are still formed
(Supplementary Figure 2D). To conﬁrm that this effect was
speciﬁcally due to impairment of migration, we transplanted
ﬂuorescently labelled neural crest cells into a stage 17 embryo and
then treated with BIO; these cells did not migrate (Fig. 2m–p).
Taken together, this demonstrated a previously under-
appreciated role for GSK3 during neural crest cell migration.
GSK3 activity favours migration of cranial neural crest. To
bypass the neural crest induction stage as well as the embryonic
lethality, we turned back to the neural crest explant cultures. We
found that dispersion of Xenopus cells was inhibited by BIO
treatment (Fig. 3a–c). Note that, in the Xenopus explants, the
pNC population can be speciﬁcally dissected independently from
the NP. We then turned back to mouse neural crest cultures in
order to better compare our pharmacological inhibitors to genetic
mutants. Treatment with two different speciﬁc inhibitors, BIO
and CHIR99021 (CHIR28) prevented neural crest cell migration
similar to that observed in Xenopus (Fig. 3d–i, Supplementary
Movies 1, 2). We found that the area covered by the pNC cells
was expanded in treated samples (Supplementary Figure 3A, 3B)
with a concurrent decrease in the migratory population (Sup-
plementary Figure 3B), suggesting a defect or delay in the cells
emigrating from the leading edge of the neuroepithelium. This
was conﬁrmed in genetic mutants, where a complete loss of GSK3
(Wnt1::cre; GSK3αﬂ/ﬂ;βﬂ/ﬂ) also led to a decrease in mNC cells
(Fig. 3j–l).
One possibility was that inhibitory serine phosphorylation of
GSK3 is necessary at the leading edge of polarized cells as has
been demonstrated in astrocytes and neurons29–32. However,
mouse mutants carrying non-phosphorylatable S21A/S9A sub-
stitutions (GSK3αS21A/S21A; GSK3βS9A/S9A) are viable, suggesting
normal neural crest migration11. Nevertheless, to conﬁrm this, we
observed that neural crest explants from these mice appear
normal and retain sensitivity to BIO inhibition, demonstrating
that serine phosphorylation of GSK3 is dispensable during neural
crest migration (Supplementary Figure 4A,B). Therefore, because
of the polarized expression of pY-GSK3 at the leading edge, we
decided to focus on the role of GSK3 as the neural crest cells
acquire their mesenchymal nature.
GSK3 inhibition perturbs the cytoskeleton. GSK3 activity has
been predicted to control cytoskeletal dynamics in a number of
systems. The loss of cell migration in mutant or BIO-treated
cultures suggested a disruption of cytoskeletal dynamics; there-
fore, we examined the actin and microtubule arrangements in
neural crest cells after inhibition of GSK3 (Fig. 3m–t). GSK3
inhibition markedly increased stress ﬁbres and concurrently
reduced leading-edge actin (Fig. 3m–p, Supplementary Fig-
ure 5A). Cell shapes at the leading edge were markedly different,
with both BIO- and CHIR-treated cells losing ﬁlamentous actin
localization, which is normally at the edge of the cell (see Fig. 3m,
o, white arrowheads) and generating spiky protrusions (Fig. 3n, p,
yellow arrowheads). Microtubule organization was also disrupted
in BIO-treated cells. In normal cells, stabilized microtubules
(marked by acetylated tubulin) extend from the centrosome
toward the leading edge of the cell (see Fig. 3q). In BIO-treated
cells, stabilized microtubules appeared to accumulate perinu-
clearly (Fig. 3r, Supplementary Figure 5C). We also examined a
marker for unstable microtubules (YL1-233) and found a sig-
niﬁcant decrease in this population, which also accumulated
primarily at the rear of the cell, behind the nucleus (Fig. 3s–t,
arrowheads and Supplementary Figure 5D). Finally, we examined
membrane dynamics in both mutants and BIO-treated explants
from mice carrying a genetically labelled membrane green
ﬂuorscent protein (GFP) (Fig. 3u–w). In the control explants, a
large proportion of the GFP was internalized within the cell,
suggesting recycling of the membrane (Fig. 3u, closed arrow-
head). Instead, both treated and mutant cells had very strong
expression of GFP at the cell membrane (Fig. 3v, w, open
arrowheads). Consistent with these ﬁndings, we also found an
accumulation of β-catenin at the membrane in BIO-treated
explants (Fig. 3x, y), suggesting that loss of GSK3 activity led to
extremely stable membrane dynamics compared to controls.
One candidate GSK-3 substrate is focal adhesion kinase (FAK),
a well-known regulator of cell motility, which controls focal
adhesion dynamics and turnover required for formation of
Fig. 2 GSK3 is required for neural crest migration in vivo. a–h mRNA in situ hybridization of Sox10, which marks migratory neural crest. a, e e9.5 mouse
embryos (n= 3). b–d, f–h e10.5 mouse embryos (n= 3). a, b, e, f Dorsal views. c, d, g, h Lateral views of e10.5 control embryos. a, b In control embryos,
Sox10 expression is absent in the brain (b, red bracket) but it is highly expressed along the embryo axis. e, f Neural crest-speciﬁc deletion of GSK3. Dorsal
view of e10.5 mutant mouse in which Sox10 expression has accumulated in the brain (f, red bracket). c, d At e10.5, Sox10 marks cranial neural crest, which
has migrated into the facial prominences (c, red arrow) and the cranial ganglia, including the trigeminal ganglia (V) and facial and acoustic nerves (VII/
VIII), glossopharyngeal nerve (IX), vagus nerve (X) and the spinal accessory nerve (XI) (d). g, h e10.5 mutant mouse lost Sox10 expression, especially in
the facial prominences (g, red arrow) and showed remarkably reduced expression in cranial ganglia and nerves X, XI. The dorsal root ganglia seem to be
unaffected. i Twist expression marks migratory neural crest. BIO treatment from st12.5 results in a loss of twist expression at st17 (frontal views, st17). BIO
treatment from st12.5 to st19 shows loss of twist expression at st20 and st26 (lateral views). The posterior streams are selectively impaired, red arrows
(n≥ 35). j BIO treatment resulted in a reduction of Alcian blue-stained facial cartilages, which are derived from neural crest (n= 12). k Twist expression
shows that cell migration is regained by stage 28, following washout from the treatment with BIO from st12.5 to st19 (n= 3). l Frontal view of a tadpole at
stage 45, previously treated with BIO (st12.5–st19). Note narrowing of the head structures and loss of the mouth (marked with red lines in control). m–p
GFP-labelled neural crest was grafted into a non-labelled embryo at stage 17 and grown to st28. GFP-labelled cells in control animals have migrated (n),
while those treated with 15 µM BIO have not migrated (o, p) (n= 3)
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branched actin (as opposed to linear actin). In motile cells, FAK is
regulated by an activating tyrosine phosphorylation and a series
of inhibitory serine phosphorylations, which are mutually
exclusive; of these, S722 is a known GSK3 target34,35. Consistent
with GSK3 roles in inhibiting FAK, we found that pY-GSK3 (in
green) and pY-FAK (in red) were mutually exclusive in the
cytoplasm (Fig. 4a, b). In addition, we found that mNC cells
ordinarily express active pY-FAK in a halo of puncta that are
oriented towards the direction of cell movement, which is
towards the right side of all ﬁgures (Fig. 4c, g, j). This punctate
expression is reminiscent of microspikes or transient actin-ﬁlled
ﬁlopods, which initiate actin nucleation ﬁlaments. The percentage
of cells with a loss of branched actin (Fig. 4l–m) and containing
pFAK at the edge was consistently reduced after GSK3 inhibition
(Fig. 4f, n, o), suggesting a loss of lamellipodia-like characteristics.
Instead, loss of GSK3 led to a striking accumulation of active
pY397-FAK in long extensions indicating persistent focal
adhesions (Fig. 4h, p–q). FAK is thought to control cytoskeletal
dynamics by repressing the function of the small GTPase Rac136.
Therefore, the inhibition of FAK activity appears necessary to
allow Rac1 activation. With the accumulation of active FAK in
our treated cells, we found that Rac1 was now excluded from the
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leading edge of the mNC cells (compare Fig. 5a to Fig. 5b,
arrowheads). Interestingly, we see an increase in Rac1 in nuclei
(Fig. 5b, c), which could indicate a more direct role for GSK3 in
subcellular localization of Rac1, possibly via phosphorylation of
the Rac1 regulator nucleophosmin/B2337,38. We saw a concurrent
loss of cdc42 localization to the leading edge of the cell (Fig. 5d,
e). Finally, since FAK and Rac1 can control lamellipodial
movement, we examined the localization of lamellipodin, which
regulates neural crest migration via the actin effectors Ena/VASP
and Scar/WAVE39,40. When GSK3 is inhibited, leading-edge
localization of lamellipodin is lost, and it also relocalizes to the
nucleus (Fig. 5f, g). As a consequence, treated neural crest cells
fail to generate stable fan-shaped lamellipodia (Fig. 5h–k, green
arrowheads), with approximately 50% of delaminated cells having
unstable lamellipodia (Fig. 5k). We then turned back to genetic
mutants to conﬁrm these phenotypes (Fig. 5l–m). In this case, to
bypass any complications of GSK3 involvement in neural crest
induction, we turned to a tamoxifen-inducible Cre (pCAAG::
CreERTM)41, allowing temporal deletions upon drug addition. As
predicted, tamoxifen-induced knockout of GSK3 led to a loss of
the wave-like lamellipodial protrusions, leaving only spiky
ﬁlopodial movements in neural crest cells (stills shown in
Fig. 5l–m and Supplementary Movies 3–5). All together, this
demonstrates that in the absence of GSK3 activity, neural crest
cells make ﬁlopodial protrusions at the expense of lamellipodia.
ALK is expressed in mNC cells. Aberrant neural crest develop-
ment is thought to underlie NB, an aggressive paediatric cancer.
Activating mutations in ALK contribute to a subset of NB cases,
correlating with poor prognosis42–47. Because we saw speciﬁc
expression of pY-GSK3 at the leading edge and in mNC cells, we
wondered whether ALK might be responsible for activating
GSK3. First, we set out to check whether ALK was expressed
during the appropriate stages of neural crest development.
Expression of ALK has previously been reported at e10.5,
including in the diencephalon and facial ganglia48; however, to
our knowledge, there has been no analysis performed during key
neural crest migration stages. To test this, we performed mRNA
in situ hybridization from e8.0 onwards (Fig. 6a, d). We found
that, by e8.5, ALK appeared speciﬁc to the NP border (NPB)
corresponding to active cranial crest migration (Fig. 6a). This
expression was enriched at the NPB consistent with a role for
ALK in the delaminating neural crest cells (Fig. 6a, d). Further-
more, ALK continues to be expressed at 9.5 days post coitum
(dpc) at the NPB and in a mNC destined for branchial arch I and
II and at the frontonasal process (Fig. 6d). Additional expression
was seen in the heart, trunk and limbs. We also examined loca-
lization of the active form of ALK protein. Using an antibody
recognizing ALK carrying a phospho-tyrosine residue (pY1507-
ALK), we again found enrichment of ALK in the right place at the
right time to be acting upon GSK3 during neural crest migration
(Fig. 6b–f). This neural crest-speciﬁc expression was recapitulated
in explant cultures, where we noted a lack of ALK protein in NPs
(total ALK, Fig. 6g) followed by an onset of expression in mNC
cells, which was somewhat nuclear, with diffuse staining
throughout the cells (compare Fig. 6h–i).
Inhibition of ALK activity leads to a loss of pY-GSK3. To test
whether ALK activity is required for tyrosine phosphorylation of
GSK3, we challenged the neural crest explants with speciﬁc
inhibitors for ALK. These included crizotinib (CTB), which is
currently used as a chemotherapeutic, and AZD3463 (AZD).
Because both of these are dual function inhibitors (CTB-blocking
ALK and the c-met receptor49,50, and AZD-blocking ALK and
insulin-like growth factor receptors51), we also treated with the
highly selective inhibitor NVP-TAE684 (NVP52) (Fig. 6l, m). We
found that blocking ALK led to a loss of pY-GSK3 expression in
neural crest explants, suggesting that GSK3 was indeed a target of
ALK kinase activity in this context (Fig. 6k, m, n). Furthermore,
in all three cases, blocking ALK function phenocopied loss of
GSK3 activity leading to a substantial decrease in delamination of
the neural crest and a loss of the migratory cell population
(Fig. 6p–s). We noted that NVP treatment was the most effective
at blocking neural crest migration while CTB had a much milder
effect (Fig. 6s). Finally, ALK inhibitors CTB and NVP phe-
nocopied the disruption of the actin cytoskeleton seen when
GSK3 was blocked (Fig. 6u–y).
NB with high levels of ALK co-express pY-GSK3. We then
wondered whether high levels of ALK activity could drive
excessive activation of GSK3. To test this, we examined nine NB
lines and found a clear correlation between levels of total ALK,
active (pY-1507) ALK and pY-GSK3 (Fig. 7a, Supplementary
Figures 6, 7). We then focussed on the Kelly NB line, which
carries an activating mutation in ALK (F1174L)53 and, as a
comparison, LS54 NB cells which had very low levels of ALK. In
western blots, we again found much higher levels of ALK in Kelly
cells, with nearly undetectable levels in LS cells, more similar to
that of mouse embryonic ﬁbroblasts (MEFs) (Fig. 7b, Supple-
mentary Figure 8).
ALK activity is required for pY-GSK3 in NB lines. All together,
our data raised the possibility that ALK regulation of GSK3 is a
neural crest-speciﬁc activity that may have been co-opted during
cancer progression. Indeed, inhibition of ALK in the NB lines also
decreased pY-GSK3 levels (Fig. 7c, Supplementary Figure 9). The
Kelly NB line carries an ALK-F1174L mutation, which renders it
somewhat insensitive to the ALK inhibitor CTB53. Therefore, as
Fig. 3 GSK3 activity is required for neural crest cell migration. a, b Neural crest cells from st 17 Xenopus embryos (n= 9). a Control explants after 8 h in
culture. b Upon GSK3 inhibition, neural crest cells spread signiﬁcantly less than the controls. c Quantiﬁcation of the distance migrated *p < 0.05. (d, g, j)
Control mouse explants. e, h Explants treated with 0.5 µm BIO or 1 µM CHIR99021, respectively. Note the decrease in area covered by migratory neural
crest (f, refers to d, e; i refers to g, h). Each dot represents one explant (**p < 0.001, unpaired t-test) j–l Mouse explants from control (j), Wnt1::cre;
GSK3aﬂ/+; GSK3bﬂ/+ (k) and Wnt1::cre; GSK3aﬂ/ﬂ; GSK3bﬂ/ﬂ complete mutants (l). Note the decrease in area covered in l (red dotted line). m–p
Filamentous actin (green) in neural crest explants. m, o Explants treated with DMSO (control) show accumulation of F-actin in lamellipodia in the leading
edge (white arrowheads). Explants treated with n 0.5 µm BIO and p 1 μM CHIR lack lamellipodia and only show stress ﬁbres at the cell edge (yellow
arrowheads). q–t Microtubules are labelled with acetylated α-tubulin or YL1-2. Controls show smooth lamellipodial edge (q) but BIO-treated cells show
spiky protrusions (r). YL1-2 tubulin in control cells is distributed all throughout the cell (s); in BIO-treated cells (t), it is found in a perinuclear zone, at the
rear of the nucleus. u Cranial neural crest explants from control e8.5 embryos carrying membrane GFP in the neural crest lineage. Migrating cells show an
elongated morphology and have a dynamic cell–cell contact (see Supplementary Movies 1, 3, 6). Membrane GFP is unstable and intracellular. v In the BIO
treatment, cells remain in contact with adjacent cells and multiple protrusions (yellow arrows). w Mutant cells carrying a neural crest-speciﬁc deletion of
GSK3 (Wnt1Cre/+; GSK3aﬂ/ﬂ; GSK3bﬂ/ﬂ) lose motility and maintain stable cell–cell contacts and membrane GFP. x, y β-Catenin staining in neural crest
explants. β-Catenin is stable in BIO-treated cells (y). a–l Scale bar= 100 µm. m–y Scale bar= 25 µM. All are representative images from at least three
independent experiments, except from j to l and w in which only one of each genotype was obtained
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with the neural crest explants, we conﬁrmed these ﬁndings using
the two other inhibitors AZD and NVP (Fig. 7c, Supplementary
Figure 9). We found that treatment with ALK inhibitors was
sufﬁcient to decrease phosphorylation of GSK3 (Fig. 7c, Supple-
mentary Figure 9B, E). Treatment with BIO or CHIR also affected
pY-GSK3 levels, consistent with some auto-regulation by GSK3
itself (Fig. 7c).
Finally, we set out to determine whether the excessive levels of
pY-GSK3 could underlie the aggressive nature of NBs. If GSK3
activity is downstream of ALK in this context, we would predict
that inhibition of GSK3 in Kelly cells would be sufﬁcient to limit
cell migration. Indeed, using scratch assays where we measured
the movement of cells, we observed that Kelly cell migration was
blocked by ALK inhibitors (NVP/AZD) similarly to GSK3
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inhibition (BIO/CHIR) (Fig. 8a, c). As noted before, Kelly cells
were resistant to CTB (Fig. 8a, c).
In contrast to the Kelly cells, LS cells, which do not carry the
ALK-F1174L variant, behaved very differently. LS cells had
substantially less pY-GSK3, which correlated with much lower
levels of active ALK (pY1507, Fig. 7a or pY1586, Supplementary
Figure 6A). LS cells were insensitive to CTB treatment (Fig. 8b, d
and Supplementary Figure 6B–D). But, while the other ALK
inhibitors led to a substantial decrease in the area covered,
examination of the cultures showed substantial cell death (see
Fig. 8b, bottom right panel). More interesting, we found that
GSK3 inhibition in LS cells elicited an unusual phenotype in the
scratch assays, with cells moving together in aggregates, rather
than as single cells (Fig. 8b, arrowheads). Our interpretation is
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that NB lines are developmentally heterogenous. Therefore, some,
like LS cells, may represent neural crest cells that have a more
'epithelial' morphology, while Kelly cells represent neural crest
cells that have fully progressed through EMT. Depending on the
developmental status of the NB line, the impact of GSK3 loss will
be different (e.g., acting via EMT versus acting via the actin
cytoskeleton and cell motility). Consistent with our hypotheses,
morphologically, the Kelly cells responded similarly to motile
neural crest cells, with BIO-treated Kelly cells appearing
compacted with dense actin staining (Fig. 8e). Nevertheless,
taken together, our data suggest that ALK activity is closely linked
to GSK3 phosphorylation and activity in primary neural crest and
NB cells.
Discussion
A key deﬁning feature of the neural crest lineage is the ability to
undergo EMT, acquire motility, migrate and, ultimately, to dif-
ferentiate into diverse cell types during embryonic development.
Aberrant neural crest development results in neurocristopathies
and other malignancies such as cancer. Thus the same migratory
characteristics could contribute to tumorigenesis and metastasis.
The understanding of cellular behaviours in the normal context
can aid our identiﬁcation of important molecules involved in
abnormal cell behaviours.
Here we studied the effect of the serine/threonine kinase GSK3
during mammalian neural crest migration. Previously, we have
found that GSK3β is required for the palate formation at speciﬁc
time points during development6. This structure depends upon
neural crest migration. However, due to functional redundancy
between GSK3α and GSK3β, the in vivo activity has been difﬁcult
to study55. Furthermore, early loss of GSK3 leads to global Wnt
activation, which can obscure later developmental roles22,23,56–58.
However, our studies bypass these early complications and pro-
vide a reﬁned understanding of the regulation and function of
GSK3. This effect on neural crest migration appears to be β-
catenin independent, as neural crest-speciﬁc expression of stabi-
lized β-catenin does not disrupt migration59. Instead, GSK3
appears to act directly on the actin cytoskeleton, changing the
dynamics of lamellipodial formation. Our data demonstrate that
this regulation may be via regulation of FAK localization, as well
as key downstream factors, including Rac1, cdc42 and lamelli-
podin. Interestingly, neural crest-speciﬁc deletion of FAK, Rac1,
cdc42 and lpd all have a range of craniofacial anomalies60,61.
However, it is worth noting that, in our assays, we predominantly
found that these proteins were relocalized, and thus it is difﬁcult
to directly compare our observations with the published null
phenotypes. Nevertheless, these observations are worth further
in-depth study.
GSK3 can also regulate the dynamics of the actin cytoskeleton,
microtubules and cell-to-matrix adhesions62. To date, polarized
inhibition via phosphorylation of S9 of GSK3β has been thought
to be the main mechanism for establishment of cell polarity,
especially in astrocytes30, and is also critical for glioma cell
invasion63. All of these scenarios depend on negative regulation
of GSK3. Importantly, contrary to the neuronal cell scenario, we
ﬁnd that GSK3 inhibition via serine phosphorylation is not
necessary for neural crest migration (Supplementary Figure 4).
However, given the complexity of GSK3 regulation, it would be
interesting to see whether combining phosphorylation mutations
on the activating tyrosines and inhibitory serines has an additive
effect on neural crest migration.
Most important, we ﬁnd that neural crest cell migration
depends on GSK3 activity and that this correlates with high levels
of tyrosine phosphorylation via ALK. While there are other
kinases that may be regulating GSK3 phosphorylation, including
GSK3 itself16, the association with ALK in the context of NB is
particularly compelling. However, future studies should include
other tyrosine kinases that may be phosphorylating GSK3. For
instance, it has been reported that PYK264, a putative Q9mammalian
homologue of ZAK1, is a kinase found in Dictyostelium shown to
phosphorylate GSK3β at Y216. However, there is still no clear
evidence on how this ﬁnding could relate to mammals. In
pathological conditions, pY216-GSK3β has been found in pros-
tate cancer, and Src was found to promote this phosphorylation,
and with it, cancer progression and invasion65. These other
kinases are worth considering in the future and may be necessary
to regulate sub-populations of GSK3.
Particularly intriguing was the prediction that GSK3α is a
putative ALK substrate in cancer cells18. ALK is negatively
associated with NB prognosis, with hyperactivating mutations of
this kinase found in some of these aggressive tumours. Therefore,
the discovery that pY-GSK3 was speciﬁcally expressed in dela-
minating and mNC cells and that this correlated with ALK-
positive NB cells was extremely exciting. The additional discovery
that ALK inhibition perturbs neural crest migration as well as the
expression of pY-GSK3 provides strong evidence for a new sig-
nalling cascade regulating neural crest cellular behaviour. Finally,
because we focussed on cell motility and lamellipodia formation,
we cannot exclude the possibility that the ALK-GSK3 pathway
has additional or longer-term effects on neural crest differentia-
tion. NB lines carrying ALK-F1174L have also has been suggested
to regulate serine (S9) phosphorylation of GSK3β via activation of
the PI3K/AKT pathway. This leads to the stabilization of MYCN
resulting in the formation of aggressive, highly penetrant
tumours43. Because this serine phosphorylation was not required
in the endogenous neural crest, we did not address the status of
inhibited (phospho-serine) GSK3 in NB cells. Nevertheless, this
Fig. 5 GSK3 is required to establish polarity and to form lamellipodia in migrating neural crest cells. a, b GSK3 inhibition increases nuclear RAC1 and
reduces cytoplasmic RAC1 in neural crest cells. a In control explants, RAC1 (red) is high in the nucleus while in the cytoplasm it is enriched at cell
protrusions (arrowheads). Actin was labelled with phalloidin (green). b In BIO-treated explants, nuclear RAC1 is high but cytoplasmic staining is lost (white
arrowheads). c Relative levels of Rac1 ﬂuorescence in the nucleus or the cytoplasm (n= 9) **p≤ 0.001 and ***p≤ 0.0001, two-tailed unpaired t-test. d–e
GSK3 inhibition reduces the expression of cdc42 in neural crest cells. d Cdc42 is cytoplasmic and perinuclear in neural crest cells. e BIO-treated explants
lose cdc42 staining. f–g In controls, anti-lamellipodin (green) stains the rufﬂed edge of migrating cells. g In contrast, BIO-treated cells show increased total
lamellipodin throughout the cell, losing speciﬁc localization at the cell edge. Scale bar, 20 μm. h, i Bright-ﬁeld still images from controls (h) or BIO-treated
samples (i) (n= 3 explants with ≥10 cells per explant). Control images show cells form fan-shaped stable lamellipodia and ready to migrate away from the
cluster (h, white arrowheads). In treated cells, despite some cells form stable lamellipodia as found in controls (i, light blue arrowheads), cells
predominantly formed an irregular protrusion that tend to retract (i, green arrowheads). Scale bar, 500 μm (see corresponding Supplementary Movies 6,
7). j Graph showing the number of cells delaminating from the premigratory neural crest cell clusters in 2 h. *p≤ 0.05 and **p≤ 0.001, two-tailed unpaired
t-test. k Percentage of delaminating cells that show stable (persistent) lamellipodia or unstable (short-lived) lamellipodia. l, m Still images of time-lapse
showing control mouse neural crest cells (l, supplementary movies 3,5) and pCAAG::creERtm ;GSK3αﬂ/ﬂ ; GSK3βﬂ/ﬂ; Rosamtmg/+ deleted cells (m,
supplementary movie 4, 5). Upon tamoxifen-induced knockout of GSK3, the neural crest cells are unable to migrate and the cell edge does not form
lamellipodia
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raises the possibility that phosphorylation events are necessary to
set up distinct pools of GSK3 within the cell, which then regulate
cell motility, transcriptional activity or protein localization.
All together, our study demonstrates that the timing and
control of active GSK3 within the embryo plays important roles
during multiple steps in neural crest development. These lessons
from the embryo improve our understanding of the pathological
misregulation of key kinases, in NB and congenital anomalies,
and may have broader implications for cell motility in diverse
systems.
Methods
Animal procedures. All animal work was performed at King’s College London in
accordance with UK Home Ofﬁce Project License 70/7441 and P8D5E2773 (KJL).
CD-1 mice were obtained from Charles River Laboratories. Mouse lines have all
been described previously and are summarized in Supplementary Table 1. In brief,
for deletion of GSK3, we used: GSK3αlacZ, GSK3βlacZ, GSK3αﬂ, and GSK3βﬂ mouse
lines. pCAGG::Cre-ERT2 and Wnt1::cre; Tg(Wnt1-cre)11Rth Cre drivers were used
and R26RmTmG as a reporter line. Genotyping was performed as described in
original publications. All mouse lines were backcrossed to CD1 to maintain con-
sistency in the background strain used. The gestational ages were determined based
on the observation of vaginal plugs, which was considered e0.5. Embryos were
further staged by counting the number of somites after dissection. For each
experiments, a minimum of three mutants with litter-matched controls were stu-
died unless otherwise noted. Sex of embryos was not determined. Xenopus laevis
embryos were cultured using standard methods66.
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Cell culture. MEFs were prepared according to standard procedures and cultured
in Dulbecco’s modiﬁed Eagle’s medium (Sigma) supplemented with 10% (v/v)
foetal bovine serum (FBS), 2mM L-glutamine, Pen/Strep, 15 mM HEPES and b-
mercaptoethanol (all from Invitrogen). NB cell lines LS and Kelly were cultured in
RPMI media supplemented with 10% (v/v) FBS and Pen/Strep. For tamoxifen-
dependent cre deletions in culture, 4-OH-tamoxifen (Sigma H7904 5 mg) was
applied at 2 μg/ml for 24 h. After the incubation period, the media was replaced
with standard media and cultured at 37 °C and 5.0% CO2. Mouse primary cranial
neural crest cultures were performed according to established protocols67.
For cranial mouse neural crest explants, dissections were performed on embryos
at 8.5 dpc and only embryos at the 5–8 somite stages were used. Brieﬂy, the embryo
was positioned to visualize and excise the neural fold. Adjacent tissues, such as
mesoderm, were carefully cleaned from the NP. The NP was then cultured on
matrigel-coated plates or slides in basal neural crest media at 37 °C, 5.0% CO2 for
24 h to allow migration of neural crest cells out of the NP. When drug treatment
was applied, it was added at plating (T= 0).
NB cell lines used are noted in Supplementary Table 2 and Supplementary
References. All cell lines were mycoplasma tested.
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Fig. 7 Neuroblastoma lines with high levels of active ALK also have high levels of pY-GSK3. aWestern blotting of neuroblastoma lines reveals levels of pY-
GSK3 correlates with levels of ALK-pY1507 (IMR5, Kelly, Be(2)C, IMR32, SH-SY-5Y, SK-N-SH). Cell lines with low or no ALK-pY1507 (SK-N-AS, LS, CHP-
212) have correspondingly low levels of pY-GSK3. b Western blotting showing that only Kelly cells have high levels of ALK when compared to mouse
embryonic ﬁbroblasts (MEFs) and LS neuroblastoma cells. c Western blotting analysis reveals that, in Kelly cell line, ALK inhibition with NVP-TAE, results
in gradual loss pYGSK-3αQ8 and pYGSK-3β, are signiﬁcantly reduced after 24 h treatment with NVP-TAE, GSK3 inhibition, using BIO or CHIR, leads to a
reduced expression of pY-GSK3, more predominantly is pY-GSK3α isoform. Some loss of ALK is also seen in NVP treatments. Treatments used were 1.5
µM crizotinib, 1.5 µM AZD-3463, 1 µM NVP-TAE-684 (NVP1), 2 µM NVP-TAE-684 (NVP2), 0.5 μM BIO and 1.0 μM CHIR99021
Fig. 6 Inhibition of ALK leads to decreased levels of pY-GSK3 in mouse neural crest. a–f ALK is expressed in the neural crest. (a, d) mRNA in situ
hybridization for Alk in e8.5 and e9.5 mouse embryos. b, c, e, f Antibody staining for activated ALK protein shows expression at the neural plate border (red
arrows) and in the branchial arches. g Staining for total ALK (green). g Very little total ALK is present in the neural plate with some present at the edge of
the premigratory neural crest (white arrowheads). h Migratory neural crest cells express higher levels of ALK. i In fully migratory NC cells, ALK appears to
be nuclear. Underneath each panel, ALK merged with Hoechst. j Co-immunostaining of pY-GSK3 (green) and ALK (red) show that ALK is expressed in all
cells that express pY-GSK3. k Treatment with the ALK inhibitor crizotinib (CTB) for 24 h reduces the levels of pY-GSK3. l, m, n, o Quantitation of loss of
pY-GSK3 and ALK ﬂuorescence using the alternative inhibitor NVP-TAE also results in a loss of mean ﬂuorescence intensity. p–s Bright-ﬁeld images of
neural crest explants treated with vehicle control or three different ALK inhibitors: 1.5 µM CTB, 1.5 µM AZD-3463, or 1 µM NVP-TAE-684. All three
treatments showed a loss of migratory neural crest (red dotted lines) (n= 3 explants with ≥10 cells per explant, scale bar= 500 µm). t Area quantiﬁcation
of the premigratory neural crest (pNC, area depicted by blue dotted lines covered in p–s) and the migratory neural crest population (mNC, red dotted
lines). A signiﬁcant reduction in mNC was seen in AZD and NVP treated explants. u–y Phalloidin staining shows F-actin structure in explants. Hoechst
marks nuclei. Note the loss of lamellipodial structures upon ALK inhibition (w, x) is comparable to BIO treatment (v) (scale bar= 25 µm). y Percentage of
cells with lamellipodial formations at the leading edge upon treatment with GSK3 inhibitor BIO or with ALK inhibitors (n= 10–20 cells per explant). Bars,
mean ± SD. One-way ANOVA and unpaired t-test *P < 0.05, **P < 0.01
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Antibodies. For the list of primary and secondary antibodies used of immuno-
ﬂuorescence and western blotting, please refer to Supplementary Table 3.
Immunoblotting. Cells were washed twice with phosphate-buffered saline (PBS)
and lysed with RIPA lysis buffer with added phosphatase inhibitor (PhosStop,
Roche) and protease inhibitor (cOmpleteTM, Roche). Protein concentrations were
determined by Bradford protein assay (BioRad). Proteins were resolved by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis on 4–12% precast gels (NuPA-
GE®Bis-Tris), then transferred to polyvinylidene diﬂuoride membrane
(IPVH00010, Millipore) using Trans-Blot® SD semi-dry transfer cell (BioRad).
Immunoblots were developed using chemiluminescent horseradish peroxidase
substrate (ECL) (Immobilon, Millipore) and ChemiDocTM Touch Imaging System
(BioRad) for detection. Densitometry was performed using the Fiji-ImageJ analysis
software, and all the values were normalized to HSP-90 control per standard
approaches. Uncropped blots can be found in Supplementary Figures 7–9.
Embryo ﬁxation and histology. Mouse embryos at e10.5 were collected in cold
PBS and ﬁxed overnight in 4% paraformaldehyde at 4 °C. Mouse embryos at e8.5,
e8.75 or e9.5 were collected in cold PBS and ﬁxed in 4% paraformaldehyde for 2 h
at 4 °C.
Samples were subsequently washed in PBS three times at room temperature
(RT) for 10 min each time, then treated as corresponding subsequent method. For
sections, samples were cryoprotected by incubating at 4 °C overnight in graded
sucrose solutions in PBS. Tissues were then embedded in Optimal Cutting
Temperature and frozen at −20 °C. Heads and bodies were sectioned at 10 μm and
frozen at −20 °C after drying at RT for 1 h. For whole mount mRNA in situ
hybridization, β-galactosidase activity and immunohistochemistry, samples were
treated according to standard procedures.
Xenopus embryos were collected at the indicated stages and ﬁxed for 1 h in
MEMFA at RT, before washing into ethanol for storage.
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Fig. 8 GSK3 and ALK inhibition affect migration in neuroblastoma cell lines. a, c Cell migration assay for Kelly neuroblastoma cell line. a Representative
bright-ﬁeld still images at start (t= 0 h) and end (t= 24 h) time points of the migration assay in Kelly cells under various GSK3 (0.5 μM BIO, 1.0 μM
CHIR99021) and ALK inhibition treatments (1.5 μM CTB, 1.5 μM AZD-3463 and 1.0 μM NVP-TAE684). c Line graph representing the percentage of wound
coverage over time. Notice that upon NVP-TAE684 (NVP) and BIO treatments cells do not close the wound as quickly as the control or unaffected CTB
samples. AZD treatment showed the lowest percentage of wound coverage. b, d Cell migration assay for LS neuroblastoma cell line. b Representative
bright-ﬁeld still images at start (t= 0 h) and end time (t= 24 h) points of the migration assay in LS cells under GSK3 inhibition (0.5 μM BIO) and ALK
inhibition treatment (1.5 μM AZD-3463). Note that upon BIO treatment LS cells tend to aggregate and expand into the wound (black arrows). d Line graph
representing the percentage of wound coverage in LS cells. There is a tendency to increase migration upon GSK3 inhibition (BIO and CHIR). The lower
wound coverage upon ALK inhibition treatment correlates with reduced population of cells at the end of the assay suggesting a compromise in cell viability
under these conditions. e Representative images of actin staining (phalloidin, green) showing Kelly cells treated with BIO compared to controls. Notice the
irregular spiky protrusions of cells where GSK3 is inhibited (yellow arrowheads). Scale bar, 25 μm
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ALK cDNA clone was obtained from Source Biosystems (ID D130039F03).
Sox10 cDNA was a gift of the Pachnis laboratory68. Life-ActGFP constructs were a
gift of the Mayor laboratory39.
Xenopus cartilage staining. Stage 45+ embryos were ﬁxed in MEMFA for 1 h at
RT before washing into ethanol. For cartilage staining, embryos were washed into a
0.15% alcian blue solution (70% EtOH/30% acetic acid) at RT for 3 days. When
suitably stained, embryos were rinsed 3 × 15 mins in 95% EtOH. Rehydration was
done stepwise into 2% KOH, then washed from 2% KOH stepwise into 80%
glycerol/20% 2%KOH, 1 h per wash before washing overnight into the ﬁnal solu-
tion. Dissection of cartilages was then performed to increase visibility of cranio-
facial cartilages.
Dissection of X. laevis neural crest and grafts. Two-cell stage embryos were
microinjected with membrane GFP or lifeact-GFP and then cultured at 15 °C until
they reached an appropriate stage. The procedure followed to obtain clean neural
crest was as Milet and Monsoro-Burq69. Neural crest explants were plated in
ﬁbronectin-covered slides to study in vitro migration. They were incubated under
control and 0.5 mM BIO at time= 0. Explants were examined 8–24 h later, as
indicated. For whole mount and grafts, the embryos were incubated in control and
15 mM BIO and collected when they reached the desired stage.
Drug treatments. All drugs were prepared at the concentration indicated, in the
corresponding standard media for each cell type. GSK3 inhibitor BIO (Calbiochem,
361550) was re-suspended in a stock solution of 140 mM in dimethyl sulphoxide
(DMSO) and stored at −20oC until use for either mouse or X. laevis experiments.
The ALK inhibitor CTB was re-suspended in a stock solution of 5.5 mM in DMSO.
The ALK inhibitor AZD3463 (Selleckchem, S7106) was re-suspended in a stock
solution of 20 mM in DMSO. All compounds were then further diluted in the
appropriate media. For MEFs and NB cell lines, treatments were added when cells
were at a conﬂuence of at least 80%. Control treatments were performed at the
corresponding DMSO concentration.
Xenopus embryos were incubated in 12-well plates, 20 embryos per well. For
GSK3 inhibition, 15 μM BIO (Calbiochem) was added to media or as otherwise
indicated. Control embryos were incubated in 0.5% DMSO in media.
NB cell scratch assay and single-cell tracking. Cells were cultured to conﬂuence
in a 96-well ImageLockTM plate (IncuCyteTM) in NB media. At this point, the cells
were starved overnight in 2% FBS. For the scratch, a 96-pin mechanical device
(WoundMaker™) was used to create homogeneous 700–800 µm wounds in the
conﬂuent monolayers after starvation. For detailed manual, see the IncuCyte® Cell
Migration Kit (Essen Bioscience). The following treatments, diluted in starvation
media, were applied to the cells prior to the scratch making: 1.5 µM AZD-3463, 1.5
µM CTB, 1.0 µM NVP-TAE684, 0.5 µM BIO, 1.0 µM CHIR 99021, and DMSO as
control. The plates were then incubated and scanned in the IncuCyte® system at
the rate of 1 scan/h for up to 36 h, but analysis was performed at the 24-h time
point. Image processing and all the analysis were made using the IncuCyte®
ZOOM Software. Signiﬁcance was based on two-tailed t-test.
Microscopy and image analysis. Live imaging was obtained using Nikon A1R.
Confocal z-stacks were obtained using a Leica TCS SP5 DM16000. Image
sequences were reconstructed using the Fiji-ImageJ analysis software.
Data availability. The authors declare that all data supporting the ﬁndings of this
study are available within the article and its supplementary information ﬁles or
from the corresponding author upon reasonable request.
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